Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn’s and Colitis Congress®
Data demonstrate that MTX-201 binds CD8 Treg, selectively eliminates pathogenic CD4 T cells, and may decrease inflammation and reduce epithelial cell damage in IBD Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation of new preclinical data for MTX-201, a bispecific antibody that antagonizes inhibitory KIR and promotes […]